ARCH Venture Fund XII, L.P. 13D and 13G filings for Prime Medicine, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-11 9:48 pm Purchase | 2025-08-07 | 13D | Prime Medicine, Inc. PRME | ARCH Venture Fund XII, L.P. | 18,587,036 10.400% | 3,075,300 (+19.83%) | Filing |
| 2024-11-22 5:32 pm Purchase | 2024-11-12 | 13D | Prime Medicine, Inc. PRME | ARCH Venture Fund XII, L.P. | 15,511,736 11.800% | 39,062 (+0.25%) | Filing |
| 2024-02-22 9:31 pm Purchase | 2024-02-15 | 13D | Prime Medicine, Inc. PRME | ARCH Venture Fund XII, L.P. | 15,472,674 12.900% | 15,472,674 (New Position) | Filing |